Fine chemical companies are increasingly interested in developing and producing pharmaceutical excipients. In their eyes, pharmaceutical excipients are no longer inactive “fillers†but new business opportunities that are full of great appeal.
At the annual meeting of the Controlled Releasing Society held in Vienna, the major fine chemicals companies have made every effort to publicize their efforts to convince major pharmaceutical manufacturers to use their accessories and promise to use these accessories. Not only can it help reduce the difficulty of the drug production process, but it can also improve the efficacy through better controlled release.
With the deepening of research, the industry’s understanding of accessories has also gradually improved. Fine Chemicals found that many traditional chemical products can often play their unique role in the pharmaceutical process. For example, Gaylord, the world's largest supplier of dimethyl sulfoxide, has historically been the largest dimethyl sulfoxide producer in the pharmaceutical industry in the United States. Originally, it used dimethyl sulfoxide as a solvent for a bulk drug. However, when the study found that dimethyl sulfoxide could promote drug absorption of transdermal preparations, Gaylord immediately switched to the production of US Pharmacopoeia standard dimethyl sulfoxide, even though the mechanism of how DMSO promotes drug absorption is not complete. Explain.
At the same time, in order to attract buyers, some specialty chemical companies have developed new pharmaceutical excipients and developed formulation technologies related to the excipients, and licensed these technologies to pharmaceutical manufacturers. Degussa is a good example. Based on its polymer excipients, the company has continuously developed three new technologies to ensure that drugs can be released within 24 hours.
In this sense, Degussa has become a new type of drug delivery service provider because it has moved away from traditional pharmaceutical excipient producers. Since Degussa started this service in 2003, there have been many pharmaceutical companies interested in this technology.
However, some traditional chemical companies still show their conservation. Although BASF and Degussa also produce high-performance polymer products, no related formulation technologies have been introduced. Relevant person in charge of the company believes that BASF's related products already have long-term market visibility and maturity, so the company does not need to develop additional technologies to sell these products, but BASF will pay attention to the latest developments in the pharmaceutical excipients sector.
Undoubtedly, when pharmaceutical excipients and drug delivery technologies are gradually becoming a highly profitable industry, fine chemical companies will naturally not miss the opportunity to vigorously develop various new excipients and drug delivery technologies, and drug manufacturers will eventually become the last Beneficiaries.
At the annual meeting of the Controlled Releasing Society held in Vienna, the major fine chemicals companies have made every effort to publicize their efforts to convince major pharmaceutical manufacturers to use their accessories and promise to use these accessories. Not only can it help reduce the difficulty of the drug production process, but it can also improve the efficacy through better controlled release.
With the deepening of research, the industry’s understanding of accessories has also gradually improved. Fine Chemicals found that many traditional chemical products can often play their unique role in the pharmaceutical process. For example, Gaylord, the world's largest supplier of dimethyl sulfoxide, has historically been the largest dimethyl sulfoxide producer in the pharmaceutical industry in the United States. Originally, it used dimethyl sulfoxide as a solvent for a bulk drug. However, when the study found that dimethyl sulfoxide could promote drug absorption of transdermal preparations, Gaylord immediately switched to the production of US Pharmacopoeia standard dimethyl sulfoxide, even though the mechanism of how DMSO promotes drug absorption is not complete. Explain.
At the same time, in order to attract buyers, some specialty chemical companies have developed new pharmaceutical excipients and developed formulation technologies related to the excipients, and licensed these technologies to pharmaceutical manufacturers. Degussa is a good example. Based on its polymer excipients, the company has continuously developed three new technologies to ensure that drugs can be released within 24 hours.
In this sense, Degussa has become a new type of drug delivery service provider because it has moved away from traditional pharmaceutical excipient producers. Since Degussa started this service in 2003, there have been many pharmaceutical companies interested in this technology.
However, some traditional chemical companies still show their conservation. Although BASF and Degussa also produce high-performance polymer products, no related formulation technologies have been introduced. Relevant person in charge of the company believes that BASF's related products already have long-term market visibility and maturity, so the company does not need to develop additional technologies to sell these products, but BASF will pay attention to the latest developments in the pharmaceutical excipients sector.
Undoubtedly, when pharmaceutical excipients and drug delivery technologies are gradually becoming a highly profitable industry, fine chemical companies will naturally not miss the opportunity to vigorously develop various new excipients and drug delivery technologies, and drug manufacturers will eventually become the last Beneficiaries.
Machine Belt Rubber,Fusing Machine Belt,Sealing Machine Belt,Silicone Rubber Seamless Belt
Taixing Yingxing Composite Material Co.,Ltd , https://www.ptfecnyx.com